ELDN — Eledon Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$2.99
-$0.02 (-0.66%)
Eledon Pharmaceuticals Inc (ELDN) is a biotechnology company listed on NASDAQ. It is led by David-Alexandre C. Gros M.D., Ph.D., based in 19800 MacArthur Boulevard, Irvine, CA, United States, 92612, with about 31 employees. Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Net income was -$17.5M. ELDN currently screens at market cap $209.6M.
Use this ELDN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ELDN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ELDN SEC filings page. Lician reads the product cache first so this HTML stays unique to Eledon Pharmaceuticals Inc even when a live quote feed is slow.
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN Key Statistics
Market Cap
$209.63M
Volume
688,823
Previous Close
$3.41
Day Range
$3.40 – $3.50
EPS
-$0.75
Revenue
$0.00
Net Income
-$36.18M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
31
ELDN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$36.18M | -$116.54M | -$87.97M | -$34.51M |
| EPS (Diluted) | -$0.75 | -$4.73 | -$6.16 | -$2.33 |
Total Assets
$177.41M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$20.55M
Operating Cash Flow
-$47.27M
Free Cash Flow
$0.00
Eledon Pharmaceuticals Inc Company Information
- CEO & Non Independent Director
- David-Alexandre C. Gros M.D., Ph.D.
- Headquarters
- 19800 MacArthur Boulevard, Irvine, CA, United States, 92612
- Website
- eledon.com
- Phone
- 949 238 8090
- IPO / Founded
- 2014-09-17
- Sector
- Healthcare
- Industry
- Biotechnology